bluebird bio (NASDAQ:BLUE) had its price target trimmed by Morgan Stanley from $190.00 to $186.00 in a research note issued to investors on Monday. The brokerage currently has an equal weight rating on the biotechnology company’s stock.

Several other research analysts also recently weighed in on the stock. Cantor Fitzgerald set a $122.00 target price on shares of bluebird bio and gave the stock a sell rating in a report on Thursday, August 23rd. Evercore ISI raised shares of bluebird bio from an in-line rating to an outperform rating and upped their target price for the stock from $175.00 to $230.00 in a report on Tuesday, June 19th. Goldman Sachs Group downgraded shares of bluebird bio from a conviction-buy rating to a buy rating in a report on Friday, September 21st. ValuEngine raised shares of bluebird bio from a buy rating to a strong-buy rating in a report on Tuesday, October 2nd. Finally, Guggenheim initiated coverage on shares of bluebird bio in a report on Monday, September 17th. They set a neutral rating for the company. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and fifteen have given a buy rating to the company. bluebird bio presently has a consensus rating of Hold and an average target price of $212.21.

Shares of bluebird bio stock opened at $126.77 on Monday. The firm has a market capitalization of $7.91 billion, a P/E ratio of -16.44 and a beta of 1.89. bluebird bio has a fifty-two week low of $120.02 and a fifty-two week high of $236.17.

bluebird bio (NASDAQ:BLUE) last issued its earnings results on Thursday, August 2nd. The biotechnology company reported ($2.91) earnings per share for the quarter, missing the consensus estimate of ($2.30) by ($0.61). The firm had revenue of $7.80 million during the quarter, compared to the consensus estimate of $10.68 million. bluebird bio had a negative return on equity of 31.57% and a negative net margin of 1,281.01%. The company’s quarterly revenue was down 53.3% on a year-over-year basis. During the same period in the prior year, the company posted ($1.73) EPS. On average, analysts expect that bluebird bio will post -10.8 earnings per share for the current fiscal year.

In other news, insider Philip D. Gregory sold 1,800 shares of the company’s stock in a transaction dated Monday, August 6th. The shares were sold at an average price of $156.61, for a total transaction of $281,898.00. Following the sale, the insider now directly owns 33,471 shares in the company, valued at approximately $5,241,893.31. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jeffrey T. Walsh sold 21,500 shares of the company’s stock in a transaction dated Thursday, August 2nd. The shares were sold at an average price of $152.02, for a total transaction of $3,268,430.00. Following the sale, the insider now owns 56,995 shares in the company, valued at $8,664,379.90. The disclosure for this sale can be found here. Insiders have sold a total of 62,859 shares of company stock valued at $10,029,606 in the last three months. Insiders own 3.00% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Nisa Investment Advisors LLC raised its position in shares of bluebird bio by 4,086.7% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,512 shares of the biotechnology company’s stock valued at $367,000 after buying an additional 2,452 shares in the last quarter. Bank of Montreal Can raised its position in shares of bluebird bio by 36.5% during the 3rd quarter. Bank of Montreal Can now owns 40,381 shares of the biotechnology company’s stock valued at $5,896,000 after buying an additional 10,790 shares in the last quarter. State of Alaska Department of Revenue raised its position in shares of bluebird bio by 9.2% during the 3rd quarter. State of Alaska Department of Revenue now owns 6,320 shares of the biotechnology company’s stock valued at $922,000 after buying an additional 530 shares in the last quarter. Atria Investments LLC purchased a new stake in shares of bluebird bio during the 3rd quarter valued at about $216,000. Finally, Public Employees Retirement System of Ohio raised its position in shares of bluebird bio by 264.9% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 31,600 shares of the biotechnology company’s stock valued at $4,960,000 after buying an additional 22,939 shares in the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

About bluebird bio

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.

Further Reading: Cash Flow Analysis in Stock Selection

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.